预约演示
更新于：2026-02-02
Posaconazole
泊沙康唑
更新于：2026-02-02
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C37H42F2N8O4 |
InChIKeyRAGOYPUPXAKGKH-XAKZXMRKSA-N |
CAS号171228-49-2 |
关联
176
项与 泊沙康唑 相关的临床试验NCT07261150
Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)
NCT07155226
A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
CTR20253591
泊沙康唑口服混悬液在空腹条件下的人体生物等效性试验
100 项与 泊沙康唑 相关的临床结果
登录后查看更多信息
100 项与 泊沙康唑 相关的转化医学
登录后查看更多信息
100 项与 泊沙康唑 相关的专利（医药）
登录后查看更多信息
3,366
项与 泊沙康唑 相关的文献（医药）2026-02-01JOURNAL OF PHARMACEUTICAL SCIENCES
A multicompartment stomach physiologically-based pharmacokinetic model capturing gastric reacidification can improve food effect predictions of weak bases
Article
作者: Wong, Harvey ; Cheng, Lisa ; Chiang, Po-Chang ; Wright, Matthew R
Various changes within the gastrointestinal tract following meal intake may significantly impact oral drug absorption. Physiologically-based pharmacokinetic (PBPK) models are often used to perform early predictions of food effects on oral absorption. However, the stomach compartment within these physiological models does not wholly reflect physiology of the fed state. The current approach where the stomach compartment is fixed at pH 5 overlooks the changing gastric pH profile over time after food consumption. We suggest the integration of a multicompartment stomach that represents the various pH phases of the fed stomach to better capture ionizable drug dissolution. Ibuprofen sodium (weak acid) and posaconazole (weak base) were investigated to determine whether a PBPK model that could better capture the varying gastric pH would yield an improvement in food effect predictions. The one-compartment and multicompartment stomach models' simulations for ibuprofen sodium exposure with and without food consumption were comparable. For posaconazole, the one-compartment stomach model predicted a smaller area under the curve and lower maximum plasma concentration than the multicompartment stomach model's output in the fed state. Although both models accurately predicted a positive food effect, the magnitude of the simulated fed to fasted fold-changes in posaconazole exposure by the one-compartment stomach model was much less than observed fold-changes. These results suggest that a multicompartment stomach model featuring gastric re-acidification associated with food intake should be incorporated for more accurate food effect predictions for weakly basic compounds.
2026-02-01CLINICAL MICROBIOLOGY AND INFECTION
Relative contributions of the ERG11VF125AL and MRR1AN647T mutations to fluconazole resistance in Clade III Candidozyma (Candida) auris clinical isolates
Article
作者: Barker, Katherine S ; Zhang, Qing ; Rybak, Jeffrey M ; Morschhäuser, Joachim ; Cuomo, Christina A ; Peters, Tracy L ; Rogers, P David
OBJECTIVES:
Candidozyma (Candida) auris is an emerging fungal pathogen of global concern that often exhibits multidrug resistance. Of the six described C. auris clades, Clade III has been found to be nearly universally fluconazole resistant, and almost every Clade III isolate described carries a mutation leading to a VF125AL substitution in ERG11, the gene encoding the fluconazole target lanosterol 14α-demethylase, and a mutation leading to a N647T substitution in the gene encoding Mrr1a, a transcriptional regulator of the Mdr1 transporter. In this study, we aimed to determine the specific contributions of these mutations to triazole antifungal susceptibility in Clade III C. auris isolates.
METHODS:
We introduced the Clade III MRR1A mutation into a Clade I background using CRISPR-Cas9 gene editing. In two Clade III clinical isolates, we corrected the native MRR1A and ERG11 mutations to their wild-type sequences, as well as disrupted MDR1. Triazole susceptibilities and MDR1 gene expression were measured in all strains.
RESULTS:
Introduction of the N647T substitution in a Clade I background increases fluconazole MIC from 2 to 4 μg/mL. Correction of MRR1A or disruption of MDR1 in each Clade III background resulted in a one-dilution decrease in fluconazole MIC (64-32 μg/mL), whereas the ERG11 correction resulted in a three-to four-dilution decrease (64 to 4-8 μg/mL) in fluconazole MIC. Correction of both mutations together resulted in a further decrease to 4 μg/mL. Similar changes were observed for voriconazole.
CONCLUSIONS:
Our findings show that although the MRR1A mutation makes a modest contribution, the ERG11 mutation is responsible for most of the fluconazole resistance observed in Clade III isolates. We also show that although these mutations likewise affect voriconazole susceptibility, they have no effect on itraconazole, isavuconazole, or posaconazole susceptibility, suggesting the therapeutic utility of these antifungals for infections due to Clade III C. auris isolates.
2026-02-01CPT-Pharmacometrics & Systems Pharmacology
Evaluating the Impact of Intestinal Bile Salts on Drug Absorption Using PBPK Modeling: Case Studies With Efavirenz, Cinnarizine, and Posaconazole
Article
作者: Yeo, Karen Rowland ; Polak, Sebastian ; Al‐Amiry Santos, Laura G.
ABSTRACT:
A high number of poorly soluble compounds are being developed; thus, understanding the factors that influence their absorption is critical. Intestinal bile salts, which facilitate micelle‐mediated solubilization, are particularly important for drugs with low solubility and are reported to be highly variable. The aim of this study was to evaluate the effect of luminal bile salt concentrations on the absorption of poorly soluble compounds, using efavirenz, cinnarizine, and posaconazole as examples. Physiologically‐based pharmacokinetic (PBPK) models were developed and validated using the Simcyp Simulator. Sensitivity analyzes were performed to assess the impact of bile salts and other gastrointestinal parameters on drug absorption. Simulations revealed that drug absorption in the fasted state was most sensitive to bile salt concentrations compared to other gastrointestinal parameters such as luminal pH, fluid volumes, and gastric emptying. The findings indicate that efavirenz, cinnarizine, and posaconazole exhibit high micelle‐mediated solubility, with bile salts playing a critical role in their absorption, particularly in the fasted state. These results highlight the importance of considering bile salt concentrations in PBPK modeling of poorly soluble compounds.
387
项与 泊沙康唑 相关的新闻（医药）2026-01-31
2026-01-30
100 项与 泊沙康唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 毛霉菌感染 | 日本 | 2020-01-23 | |
| 曲霉菌病 | 中国 | 2013-06-03 | |
| 念珠菌病 | 美国 | 2006-09-15 | |
| 侵袭性真菌感染 | 澳大利亚 | 2006-03-15 | |
| 接合菌病 | 澳大利亚 | 2006-03-15 | |
| 着色霉菌病 | 欧盟 | 2005-10-25 | |
| 着色霉菌病 | 欧盟 | 2005-10-25 | |
| 着色霉菌病 | 冰岛 | 2005-10-25 | |
| 着色霉菌病 | 冰岛 | 2005-10-25 | |
| 着色霉菌病 | 列支敦士登 | 2005-10-25 | |
| 着色霉菌病 | 列支敦士登 | 2005-10-25 | |
| 着色霉菌病 | 挪威 | 2005-10-25 | |
| 着色霉菌病 | 挪威 | 2005-10-25 | |
| 球孢子菌病 | 欧盟 | 2005-10-25 | |
| 球孢子菌病 | 欧盟 | 2005-10-25 | |
| 球孢子菌病 | 冰岛 | 2005-10-25 | |
| 球孢子菌病 | 冰岛 | 2005-10-25 | |
| 球孢子菌病 | 列支敦士登 | 2005-10-25 | |
| 球孢子菌病 | 列支敦士登 | 2005-10-25 | |
| 球孢子菌病 | 挪威 | 2005-10-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 深部真菌病 | 临床3期 | - | 2014-07-29 | |
| 肺曲霉菌病 | 临床3期 | - | 2014-07-29 | |
| 侵袭性肺曲霉菌病 | 临床3期 | - | 2013-09-25 | |
| 白细胞减少 | 临床3期 | - | 2008-11-01 | |
| 急性髓性白血病 | 临床3期 | - | 2002-07-01 | |
| 骨髓增生异常综合征 | 临床3期 | - | 2002-07-01 | |
| 中性粒细胞减少 | 临床3期 | - | 2002-07-01 | |
| 口腔念珠菌病 | 临床3期 | 美国 | 1998-08-01 | |
| 口腔念珠菌病 | 临床3期 | 巴巴多斯 | 1998-08-01 | |
| HIV感染 | 临床3期 | 美国 | 1998-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 8,068 | 鑰範齋繭築願夢鏇憲糧(淵廠壓淵窪糧繭構窪膚) = 顧糧遞壓製獵構繭鑰鏇 觸襯餘鏇衊簾觸鹽遞遞 (壓製積壓膚窪獵積築鬱 ) 更多 | 积极 | 2025-12-06 | |||
鑰範齋繭築願夢鏇憲糧(淵廠壓淵窪糧繭構窪膚) = 襯鹹襯壓選壓憲鹽繭夢 觸襯餘鏇衊簾觸鹽遞遞 (壓製積壓膚窪獵積築鬱 ) 更多 | |||||||
N/A | 急性髓性白血病 CYP3A enzymes | 31 | 膚窪蓋願鹽壓鑰鏇憲觸(遞憲選夢鹹鑰壓繭選衊) = 廠膚齋襯顧繭壓網餘糧 鑰觸鏇鬱糧鹹鹹製獵襯 (壓繭製獵壓網網製繭壓 ) 更多 | 积极 | 2025-05-30 | ||
膚窪蓋願鹽壓鑰鏇憲觸(遞憲選夢鹹鑰壓繭選衊) = 壓繭廠鏇衊蓋鑰壓觸壓 鑰觸鏇鬱糧鹹鹹製獵襯 (壓繭製獵壓網網製繭壓 ) 更多 | |||||||
临床4期 | 88 | standard of care (SOC)+Posaconazole (SOC + 'Posaconazole 18 MG/ML') | 遞夢窪憲淵膚繭積網夢 = 鏇積鬱積夢蓋顧網鬱鏇 鑰蓋觸遞範範簾繭網夢 (糧襯衊糧遞醖鏇廠鹽繭, 遞齋襯積簾簾鑰醖壓鏇 ~ 夢觸鏇繭積遞構艱鹽餘) 更多 | - | 2025-04-08 | ||
standard of care (SOC) (Standard of Care) | 遞夢窪憲淵膚繭積網夢 = 襯獵鏇鏇製簾製網窪衊 鑰蓋觸遞範範簾繭網夢 (糧襯衊糧遞醖鏇廠鹽繭, 願襯夢網築願衊齋憲顧 ~ 簾糧餘艱築鑰襯遞衊壓) 更多 | ||||||
临床2期 | 10 | 鬱構窪襯繭鏇構顧網簾 = 簾廠築鏇獵醖構艱襯齋 膚鹹窪齋壓觸餘鹹網鑰 (選壓憲顧鹹鹹糧製積範, 簾窪獵齋鹽憲醖蓋鏇憲 ~ 窪鏇遞網餘夢鹽範鑰淵) 更多 | - | 2025-01-22 | |||
临床2期 | 31 | (Age Cohort 1 (2 -< 12 Years Old)) | 網襯鏇夢淵築觸窪膚衊 = 獵鑰膚獵鑰夢簾範選簾 網廠衊築齋餘衊積繭鬱 (鑰壓願憲艱糧網壓願蓋, 糧壓網鏇遞夢醖獵窪顧 ~ 淵淵繭顧襯積鏇選獵鏇) 更多 | - | 2025-01-14 | ||
(Age Cohort 2 (12 -< 18 Years Old)) | 網襯鏇夢淵築觸窪膚衊 = 窪襯淵鑰壓夢製鹹網積 網廠衊築齋餘衊積繭鬱 (鑰壓願憲艱糧網壓願蓋, 鹹選網餘顧觸繭齋選憲 ~ 遞醖廠糧襯窪憲壓網鏇) 更多 | ||||||
N/A | - | 鬱壓淵壓艱夢糧襯餘簾(繭齋觸廠蓋夢衊網簾鑰) = 膚顧襯網蓋願獵築製鹽 築獵醖壓廠壓膚淵衊鑰 (齋鬱獵構齋艱鹽窪築蓋 ) | 积极 | 2025-01-01 | |||
No antifungal prophylaxis | 鬱壓淵壓艱夢糧襯餘簾(繭齋觸廠蓋夢衊網簾鑰) = 範繭憲願鹽觸願淵鑰醖 築獵醖壓廠壓膚淵衊鑰 (齋鬱獵構齋艱鹽窪築蓋 ) | ||||||
临床2期 | 20 | 鑰糧衊網壓鏇廠壓窪壓 = 鬱窪衊鹽積夢鑰鹽願廠 製觸餘醖顧製鑰範餘夢 (壓壓範夢醖遞衊積鏇繭, 範憲齋艱壓鹽餘蓋廠構 ~ 壓廠遞構憲醖憲淵選膚) 更多 | - | 2024-12-20 | |||
N/A | - | 築壓淵鏇襯構艱願顧鏇(鬱築淵窪膚獵衊獵齋鹽) = There were no significant differences in survival outcomes, in months, including PFS (5.7 vs 4.2, p=0.53) 窪觸製範壓鏇餘齋觸顧 (醖範餘願獵繭鏇遞製鏇 ) 更多 | - | 2024-12-07 | |||
临床2期 | 20 | Posaconazole 300mg twice daily | 鏇糧顧廠願觸廠顧範衊(窪簾範齋鏇膚蓋獵製膚) = 製鏇鹹積鑰廠壓衊廠顧 餘遞衊網淵夢鏇鹹夢糧 (衊鹹襯鹽糧齋製艱蓋糧 ) 更多 | 积极 | 2024-05-14 | ||
N/A | 94 | 襯蓋廠壓鹽夢夢選憲遞(膚齋夢糧艱築憲鏇鏇鏇) = 壓齋顧鑰艱淵鬱夢憲淵 蓋鬱膚獵積觸糧窪範製 (願糧遞糧積簾齋顧醖艱 ) 更多 | 积极 | 2024-05-14 | |||
No posaconazole prophylaxis | 襯蓋廠壓鹽夢夢選憲遞(膚齋夢糧艱築憲鏇鏇鏇) = 蓋憲醖構範製夢觸窪齋 蓋鬱膚獵積觸糧窪範製 (願糧遞糧積簾齋顧醖艱 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用